Predictive multi-biomarker discovery platform (GBLscan™):
Our AI-based approach identifies predictive “multi-gene” biomarker for efficacy and safety from patient data during early phase clinical trials. AI driven prediction model enhances the clinical trial success and enables biomarker-guided indication expansion/drug repositioning

Home page of this offering   provided by Syntekabio